Congruence Therapeutics, a Canada-based biotechnology company, announced on Tuesday that it has named Sharath S Hegde, PhD as its new chief scientific officer.
Dr Hegde has served as chief scientific officer at Herophilus and chief scientific officer of Recursion. He has spent more than 15 years at Theravance Biopharma, where he rose from positions of increasing responsibility to assume the role of senior vice president and head of Research. He has served at Syntex Corporation for nine years.
Dr Hegde has PhD in Pharmacology from the University of Houston and B.Pharm/M.Pharm from the University of Mumbai.
BioArctic reports EMA acceptance of MAA for lecanemab in early Alzheimer's disease
Sanofi and Regeneron's Dupilumab recommended for expanded EU approval
Genetesis Makes New Appointments to Executive Leadership Team
Sling Therapeutics names new chief medical officer
Annovis Bio reveals patient enrolment update for Phase three buntanetap study
Brukinsa Approved in the US for Chronic Lymphocytic Leukemia